Patents Assigned to Amgen
  • Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
    Patent number: 11072640
    Abstract: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 27, 2021
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • IN-LINE MEASUREMENT OF FILL SYSTEM
    Publication number: 20210223082
    Abstract: The field of the invention relates generally to filling containers with liquid. More specifically, the invention relates to the real-time assessment of the volume filled into containers, particularly in the manufacture of medicaments such as pharmaceuticals. The invention finds specific use in the final stage of drug manufacturing known as fill/finish wherein the drug substance or active pharmaceutical intermediate is prepared as a final drug product in a formulation suitable for administration to patients in need of the same, which is then provided to patients. More particularly, the invention relates to controlling the volume in container via in-line non-destructive monitoring of the fill process.
    Type: Application
    Filed: June 6, 2019
    Publication date: July 22, 2021
    Applicant: AMGEN INC.
    Inventors: Joseph BERNACKI, Daniel MARSIGLIO, Nitin RATHORE
  • Methods of treating cardiovascular disease with an anti-ASGR antibody or binding fragments thereof
    Patent number: 11066472
    Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 20, 2021
    Assignee: Amgen Inc.
    Inventors: Paul Nioi, Peter Coward, Christopher Murawsky
  • Low-viscosity antigen binding proteins and methods of making them
    Patent number: 11059908
    Abstract: The present invention concerns a method for preparing antigen binding proteins with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: July 13, 2021
    Assignee: AMGEN INC.
    Inventors: Joon Hoi Huh, Riki Stevenson, Pavel Bondarenko, Andrew Nichols, Da Ren, Neeraj Jagdish Agrawal
  • ST2 antigen binding proteins
    Patent number: 11059895
    Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: July 13, 2021
    Assignee: Amgen Inc.
    Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
  • Injector and method of assembly
    Patent number: 11058821
    Abstract: An injector may include a container having a wall with an interior surface and a seal assembly with an interior surface, the interior surfaces of the wall and the seal assembly defining a closed sterile reservoir filled with a drug product. The injector may also include a fluid delivery system comprising a clean, unsheathed, rigid container needle having a point disposed only partially through the seal assembly in a storage state, and disposed through the interior surface of the seal assembly into the sterile reservoir in a delivery state. Further, the injection may include an actuator that is adapted to move the container needle from the storage state to the delivery state.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: July 13, 2021
    Assignee: AMGEN INC.
    Inventors: Francisca Tan-Malecki, Ronald Forster, Scott M. Nunn, Mark D. Holt, Son C. Tran, Sheldon Moberg
  • Formulation for bispecific T-cell engagers (BiTEs)
    Patent number: 11052128
    Abstract: The present invention relates to stable pharmaceutical compositions which contain polypeptides having at least two antigen-binding domains and are especially suited for subcutaneous administration. The invention provides liquid compositions which minimize the formation of undesired polypeptide aggregates (dimers and/or multimers). The present invention further provides a method for minimizing the aggregation of polypeptides having antigen-binding domains in liquid compositions.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: July 6, 2021
    Assignee: AMGEN INC.
    Inventors: Carsten Olbrich, Thomas Bunte, Jonas Winter, Jörg Peters, Thomas Trill
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11053226
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: July 6, 2021
    Assignee: AMGEN INC.
    Inventors: Youngsook Shin, Victor J. Cee, Christopher M. Tegley, Brian Alan Lanman, Ryan Paul Wurz, Kevin C. Yang, Vu Van Ma, Daniel Erlanson, Joon Won Jeong, Raymond V. Fucini, Jeffrey Iwig
  • Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
    Patent number: 11053318
    Abstract: The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 6, 2021
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Peter Kufer, Roman Kischel, Marion Subklewe, Christina Heitmueller
  • Antibodies targeting CDH19 for melanoma
    Patent number: 11053311
    Abstract: The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human CDH19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the disclosure relates to a process for the production of the antibody construct of the disclosure, a medical use or a method of treatment using the antibody construct and a kit comprising the antibody or antigen binding fragment thereof or the antibody construct.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: July 6, 2021
    Assignee: AMGEN INC.
    Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan
  • Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
    Patent number: 11046774
    Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 29, 2021
    Assignee: AMGEN INC.
    Inventors: Junming Yie, Donghui Shi, David J. Lloyd, Jinghong Wang, Glenn N. Sivits, Jr., Murielle M. Veniant-Ellison, Renee Komorowski, Neeraj Agrawal, Darren L. Bates, Brandon C. P. Clavette, Ian N. Foltz, Shu-yin Ho, Christopher Murawsky, Xiaoshan Min, Zhulun Wang
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11045484
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: June 29, 2021
    Assignee: Amgen Inc.
    Inventors: Ryan Paul Wurz, Victor J. Cee, Albert Amegadzie, Ning Chen, Brian Alan Lanman, Michael D. Bartberger
  • Heteroaryl-substituted triazoles as APJ receptor agonists
    Patent number: 11046680
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 29, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Frank Kayser, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Kevin Yang, Wen-Chen Yeh
  • Synthesis of omecamtiv mecarbil
    Patent number: 11040956
    Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 22, 2021
    Assignee: AMGEN INC.
    Inventors: Sebastien Caille, Kyle Quasdorf, Philipp Roosen, Xianqing Shi, Andrew Cosbie, Fang Wang, Zufan Wu, Archana Neergunda, Bin Peter Quan, Lianxiu Guan
  • High concentration antibody formulations
    Patent number: 11040102
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 22, 2021
    Assignee: AMGEN INC.
    Inventor: Timothy David Osslund
  • Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
    Patent number: 11040024
    Abstract: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (?) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-? or the inhibition of PDE4.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: June 22, 2021
    Assignee: AMGEN INC.
    Inventors: George W. Muller, Peter H. Schafer, Hon-Wah Man, Chuansheng Ge
  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20210179722
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20210179723
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, Jr., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • Single-use auto-injector
    Patent number: 11033684
    Abstract: A single-use auto-injector includes a housing and a dosing unit in at least part of the housing. The dosing unit includes a needle, a drug container with drug, a piston movable in the container, a first mechanical power supply for moving the piston to deliver the drug, an activation mechanism, and a mechanical escapement mechanism for controlling the movement of the piston. The auto-injector has a first state in which the needle is protected from needle damage or contamination, a second state in which the needle is ready to penetrate a human body, a third state in which the needle has penetrated the human body and is ready to dose, and a fourth state in which the needle is shielded to avoid unintended needle sticks. A second mechanical power supply is configured to shift state of the auto-injector from the third state to the fourth state.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: June 15, 2021
    Assignee: AMGEN INC.
    Inventors: Hans Stenberg Knudsen, Christian Plambech, Rasmus Øhlenschlæger, Jørgen Jørgensen
  • Autoinjector with removable cap
    Patent number: D922567
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: June 15, 2021
    Assignee: AMGEN INC.
    Inventors: Margaux Frances Boyaval, Sigrid Moeslinger, Masamichi Udagawa